» Articles » PMID: 25962684

Role of Chemokine CX3CL1 in Progression of Multiple Myeloma Via CX3CR1 in Bone Microenvironments

Overview
Journal Oncol Rep
Specialty Oncology
Date 2015 May 13
PMID 25962684
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Several chemokines/chemokine receptors such as CXCL12, CCL3, CXCR4 and CCR1 attract multiple myelomas to specific microenvironments. In the present study, we investigated whether the CX3CL1/CX3CR1 axis is involved in the interaction of the multiple myeloma cells with their microenvironment. The expression of CX3CR1 (also known as fractalkine) was detected in three of the seven human myeloma cell lines. CX3CL1-induced phosphorylation of Akt and ERK1/2 was detected in the CX3CR1-positive cell lines, but not in the CX3CR1-negative cell lines. In addition, CX3CL1-induced cell adhesion to fibronectin and vascular cell adhesion molecule-1 (VCAM-1) in the human myeloma RPMI-8226 cell line. We also investigated whether a relationship existed between myeloma cells and osteoclasts that may function via the CX3CL1/CX3CR1 axis. Conditioned medium from CX3CL1-stimulated RPMI-8226 cells drastically increased the osteoclast differentiation. Collectively, the results from the present study support the concept of the CX3CL1-mediated activation of the progression of the multiple myeloma via CX3CR1. Thus, CX3CR1 may represent a potential therapeutic target for the treatment of multiple myeloma in a bone microenvironment.

Citing Articles

In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?.

Mattioda C, Voena C, Ciardelli G, Mattu C Cells. 2025; 14(1.

PMID: 39791739 PMC: 11720277. DOI: 10.3390/cells14010038.


Fractalkine in Health and Disease.

Rodriguez C, Chocarro L, Echaide M, Ausin K, Escors D, Kochan G Int J Mol Sci. 2024; 25(15).

PMID: 39125578 PMC: 11311528. DOI: 10.3390/ijms25158007.


The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy.

Chaudhri A, Bu X, Wang Y, Gomez M, Torchia J, Hua P Front Immunol. 2023; 14:1237715.

PMID: 37771579 PMC: 10524267. DOI: 10.3389/fimmu.2023.1237715.


MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis.

Katsarou A, Trasanidis N, Ponnusamy K, Kostopoulos I, Alvarez-Benayas J, Papaleonidopoulou F Blood Adv. 2023; 7(21):6395-6410.

PMID: 37224458 PMC: 10598502. DOI: 10.1182/bloodadvances.2023009772.


A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).

Sun Y Front Genet. 2023; 14:1183795.

PMID: 37153002 PMC: 10157490. DOI: 10.3389/fgene.2023.1183795.